|
| Clinical efficacy and safety of Xinhuang Tablet for herpes zoster: a system evaluation |
| Hits 415 Download times 777 Received:July 30, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2023.11.15 |
| Key Words
herpes zoster;Xinhuang Tablet;system evaluation;Meta-analysis;randomized controlled trial |
| Author Name | Affiliation | E-mail | | DING Zhiming | Ulcers and Peripheral Vascular Surgery Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | | | ZHANG Chenyue | School of Statistics and Data Science, Nankai University, Tianjin, 300071, China | | | WANG Hui | Evidence Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | wangh@tice.com.cn |
|
| Abstract
|
| [Objective] To systematically evaluate the efficacy and safety of Xinhuang Tablets in the treatment of herpes zoster. [Methods] A computer search was conducted on PubMed, EMbase, the Cochrane, Library, CNKI, WanFang Data, CBM, and VIP databases to search for randomized controlled trials(RCTs) on the efficacy and safety of Xinhuang Tablets in the treatment of herpes zoster. The search period was from the establishment of the database to February 7, 2023. After two researchers independently screened the literature, extracted data, and evaluated the risk of bias included in the study, a Meta-analysis was conducted using RevMan 5.4 software. [Results] A total of 10 RCTs were included, including 820 patients. Meta-analysis results showed that Xinhuang Tablet combined with conventional Western therapy compared with conventional Western therapy alone can reduce the VAS score of patients with herpes zoster [MD=-0.93, 95%CI(-1.57, -0.28), P=0.005], significantly improve the total effective rate [RR=1.24, 95%CI(1.12, 1.37), P<0.0001] and the cure rate [RR=1.68, 95%CI(1.43, 1.96), P<0.000 01], shorten the pain relief time [MD=-2.13, 95%CI(-3.02, -1.23), P<0.000 01], the blister arrest time [MD=-1.50, 95%CI(-2.70, -0.29), P=0.02], the scab formation time [MD=-2.03, 95%CI (-2.94, -1.11), P<0.000 1], and the recovery time [MD=-2.27, 95%CI(-3.27, -1.27), P<0.000 1]. There was no significant difference in the incidence of adverse reactions between the Xinhuang Tablet combined group and the conventional group. [Conclusion] The existing evidence indicates that Xinhuang Tablet combined with routine Western treatment can reduce VAS pain score, improve the effective rate and cure rate of treatment, shorten the time for pain relief, blister arrest, scab formation, and recovery of herpes zoster, and has good safety. Due to the limitations of the number and quality of included studies, the above conclusions need to be verified by more high-quality studies. |
|
|
|
|
|
|
|
